A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of intermittent oral Xeloda administration in
combination with irinotecan as a first-line treatment in patients with advanced and/or
metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months and the
target sample size is <100 individuals.